卡尔加里，阿尔伯塔省 --（Newsfile Corp. -2026 年 4 月 17 日）- Marvel Biosciences Corp. (TSXV: MRVL)（“ Marvel” 或 “ 公司”）今天宣布已完成之前宣布的无中介私人配售无担保可转换债券（“ 债券”），总收益为 500,000 美元（“ 发行”），待 TSX 风险交易所的最终批准。
债券的年利率为 12%，按年支付，至 2027 年 12 月 31 日到期。利息可由公司选择以现金或公司普通股（“ 普通股”）支付，基于支付日前 3 天在 TSX 风险交易所的普通股 20 日成交量加权平均交易价格，受 TSX 风险交易所允许的最低价格限制（并需获得 TSX 风险交易所的批准）。债券可由持有人选择按每股 0.17 美元的转换价格转换为普通股。如果普通股在 TSX 风险交易所的成交量加权平均交易价格在至少 10 个连续交易日内达到每股至少 0.60 美元（无论这些天是否有交易），公司可以强制将债券转换为普通股。
与本次发行相关的所有证券均需遵守于 2026 年 8 月 17 日到期的持有期。发行的净收益将用于药物配方、毒理学研究和一般营运资金。
关于 Marvel Biosciences Corp. Marvel Biosciences Corp.及其全资子公司 Marvel Biotechnology Inc.是一家总部位于卡尔加里的临床前阶段制药开发生物技术公司。该公司正在开发 MB 204，这是一种新型氟化衍生物，源自已批准的抗帕金森药物 Istradefylline，这是唯一获得临床批准的腺苷 A2a 拮抗剂。大量不断增长的科学证据表明，阻断腺苷 A2a 受体的药物，如 MB-204，可能对治疗其他神经系统疾病（如自闭症、抑郁症和阿尔茨海默病）有用。该公司正在积极研究其在解决其他神经发育障碍（如雷特综合症和脆性 X 综合症）方面的潜力，以扩大其治疗范围。
联系信息：
Marvel Biosciences Corp. J. Roderick (Rod) Matheson，首席执行官或
Dr. Mark Williams，总裁兼首席科学官
电话：403 770 2469
无论是 TSX 风险交易所还是其监管服务提供者（根据 TSX 风险交易所政策的定义）均不对本公告的充分性或准确性承担责任。
前瞻性声明 本新闻稿包含某些构成前瞻性声明或信息（“前瞻性声明”）的陈述，包括关于 Marvel 的业务、发行及私人配售收益使用的声明。这些前瞻性声明受到许多风险和不确定性的影响，其中一些超出了 Marvel 的控制范围，包括一般经济状况的影响、Marvel 普通股的当前股价、TSX 风险交易所的接受程度和市场对私人配售的接受程度、行业状况、货币波动、合格人员或管理层的缺乏、股市波动以及从内部和外部来源获取足够资本的能力。尽管 Marvel 相信其前瞻性声明中的预期是合理的，但这些预期基于对未来事件的因素和假设，这些因素和假设可能被证明是不准确的。这些因素和假设基于当前可用的信息。这些声明受到已知和未知的风险、不确定性和其他因素的影响，可能会影响实际结果或事件，并导致实际结果或事件与所述、预期或暗示的前瞻性信息有重大差异。因此，读者被提醒不要对前瞻性信息过度依赖，因为无法提供未来结果、活动水平或成就的保证。本文件中包含的前瞻性声明是在本文件日期作出的，除非法律要求，Marvel 不承担任何公开更新或修订所包含的前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。本文档中包含的前瞻性声明明确受到本警示声明的限制。
<img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8156/293094_9ec8cc0334b54a84_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8156/293094_9ec8cc0334b54a84_logo.jpg"/>
要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/293094
<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/293094/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/293094/375"/>

Assembly生物科技

LEXX

Marvel Biosciences Corp. 已完成一项非承销的无担保可转换债券私募，筹集资金为 500,000 美元。该债券的年利率为 12%，到期日为 2027 年 12 月 31 日。债券可按每股 0.17 美元转换为普通股，如果股价连续 10 天超过 0.60 美元，则将强制转换。筹集的资金将用于药物配方和毒理学研究。所有证券均需遵守持有期，直至 2026 年 8 月 17 日

Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL)(&#34; Marvel&#34; or the &#34; Company&#34;) announced today that it has completed the closing of the previously announced non-brokered private placement of unsecured convertible debentures (&#34; Debentures&#34;) for gross proceeds of $500,000 (the &#34; Offering&#34;), subject to final approval of the TSX Venture Exchange.
<div class="lb-trans">卡尔加里，阿尔伯塔省 --（Newsfile Corp. -2026 年 4 月 17 日）- Marvel Biosciences Corp. (TSXV: MRVL)（“ Marvel” 或 “ 公司”）今天宣布已完成之前宣布的无中介私人配售无担保可转换债券（“ 债券”），总收益为 500,000 美元（“ 发行”），待 TSX 风险交易所的最终批准。
</div>The Debentures bear interest at the rate of twelve percent (12%) per annum, payable annually and mature on December 31, 2027. Interest may be repaid in cash or common shares of the Corporation (&#34; Common Shares&#34;), at the option of the Corporation, based on the 20 day volume weighted average trading price of the Common Shares on the TSX Venture Exchange, calculated 3 days prior to the payment date, subject to the minimum price permitted by the TSX Venture Exchange (and subject to approval of the TSX Venture Exchange). The Debentures are convertible at the holder's option into Common Shares at a conversion price of $0.17 per Common Share. The Corporation can force conversion of the Debentures into Common Shares if the volume weighted average trading price of the Common Shares on the TSX Venture Exchange is at least $0.60 per Common Share for a minimum of 10 consecutive trading days (whether or not trading occurs on such days).
<div class="lb-trans">债券的年利率为 12%，按年支付，至 2027 年 12 月 31 日到期。利息可由公司选择以现金或公司普通股（“ 普通股”）支付，基于支付日前 3 天在 TSX 风险交易所的普通股 20 日成交量加权平均交易价格，受 TSX 风险交易所允许的最低价格限制（并需获得 TSX 风险交易所的批准）。债券可由持有人选择按每股 0.17 美元的转换价格转换为普通股。如果普通股在 TSX 风险交易所的成交量加权平均交易价格在至少 10 个连续交易日内达到每股至少 0.60 美元（无论这些天是否有交易），公司可以强制将债券转换为普通股。
</div>All securities issued in connection with the Offering are subject to a hold period that expires on August 17, 2026. The net proceeds from the Offering will be used for drug formulation, toxicology studies and for general working capital purposes.
<div class="lb-trans">与本次发行相关的所有证券均需遵守于 2026 年 8 月 17 日到期的持有期。发行的净收益将用于药物配方、毒理学研究和一般营运资金。
</div>About Marvel Biosciences Corp. Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB 204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
<div class="lb-trans">关于 Marvel Biosciences Corp. Marvel Biosciences Corp.及其全资子公司 Marvel Biotechnology Inc.是一家总部位于卡尔加里的临床前阶段制药开发生物技术公司。该公司正在开发 MB 204，这是一种新型氟化衍生物，源自已批准的抗帕金森药物 Istradefylline，这是唯一获得临床批准的腺苷 A2a 拮抗剂。大量不断增长的科学证据表明，阻断腺苷 A2a 受体的药物，如 MB-204，可能对治疗其他神经系统疾病（如自闭症、抑郁症和阿尔茨海默病）有用。该公司正在积极研究其在解决其他神经发育障碍（如雷特综合症和脆性 X 综合症）方面的潜力，以扩大其治疗范围。
</div>Contact Information:
<div class="lb-trans">联系信息：
</div>Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer or
<div class="lb-trans">Marvel Biosciences Corp. J. Roderick (Rod) Matheson，首席执行官或
</div>Dr. Mark Williams, President, and Chief Science Officer
<div class="lb-trans">Dr. Mark Williams，总裁兼首席科学官
</div>Tel: 403 770 2469
<div class="lb-trans">电话：403 770 2469
</div>Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
<div class="lb-trans">无论是 TSX 风险交易所还是其监管服务提供者（根据 TSX 风险交易所政策的定义）均不对本公告的充分性或准确性承担责任。
</div>Forward-Looking Statements This press release contains certain statements which constitute forward-looking statements or information (&#34;forward-looking statements&#34;), including statements regarding Marvel's business, the Offering, including the use of proceeds of the Private Placement. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Marvel's control, including the impact of general economic conditions, the current share price of Marvel's common shares, TSX Venture acceptance and market acceptance of the Private Placement, industry conditions, currency fluctuations, the lack of availability of qualified personnel or management, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Marvel believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking information. As such, readers are cautioned not to place undue reliance on the forward-looking information, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this document are made as of the date of this document and, except as required by applicable law, Marvel does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.
<div class="lb-trans">前瞻性声明 本新闻稿包含某些构成前瞻性声明或信息（“前瞻性声明”）的陈述，包括关于 Marvel 的业务、发行及私人配售收益使用的声明。这些前瞻性声明受到许多风险和不确定性的影响，其中一些超出了 Marvel 的控制范围，包括一般经济状况的影响、Marvel 普通股的当前股价、TSX 风险交易所的接受程度和市场对私人配售的接受程度、行业状况、货币波动、合格人员或管理层的缺乏、股市波动以及从内部和外部来源获取足够资本的能力。尽管 Marvel 相信其前瞻性声明中的预期是合理的，但这些预期基于对未来事件的因素和假设，这些因素和假设可能被证明是不准确的。这些因素和假设基于当前可用的信息。这些声明受到已知和未知的风险、不确定性和其他因素的影响，可能会影响实际结果或事件，并导致实际结果或事件与所述、预期或暗示的前瞻性信息有重大差异。因此，读者被提醒不要对前瞻性信息过度依赖，因为无法提供未来结果、活动水平或成就的保证。本文件中包含的前瞻性声明是在本文件日期作出的，除非法律要求，Marvel 不承担任何公开更新或修订所包含的前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。本文档中包含的前瞻性声明明确受到本警示声明的限制。
</div><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8156/293094_9ec8cc0334b54a84_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8156/293094_9ec8cc0334b54a84_logo.jpg"/>
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293094
<div class="lb-trans">要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/293094
</div><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/293094/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/293094/375"/>

Marvel Biosciences 宣布完成可转换债券的发行 | MBCOF 股票新闻